Opportunity overview
The Contracting Authority is procuring a targeted prostate cancer screening pathway with a focus on men at increased risk due to an inherited BRCA2 variant utilising the competitive provider selection process under the Health Care Services (Provider Selection Regime) Regulations 2023.<br/><br/>NHS England is seeking a provider to deliver a national centralised Prostate MRI Reporting Service to support the Targeted Prostate Cancer Screening Programme for England.<br/><br/>The service will provide specialist reporting of prostate MRI examinations for Programme Participants requiring MRI following an above-threshold PSA result. The scope will include image receipt or access, case acceptance, specialist human double reporting, lesion delineation where required, expert arbitration, structured report production and authorisation, secure report return, acknowledgement and Failsafe arrangements, quality assurance, escalation, Programme data reporting, audit and governance participation.<br/><br/>Diagnostic MRI scanning is outside the scope of this procurement. The procurement also excludes PSA testing, biopsy delivery, urology treatment, BRCA digital decision-resource development, BRCA genetic testing and development of the national Programme IT system.
Classification
- CPV85150000 — Medical imaging services
Lots
- As part of this process, the Contracting Authority would like to invite interested parties to read and complete our Invitation to Tender within our e-Tendering System Atamis, https://atamis-1928.my.site.com/s/Welcome. This service will be competed under The Health Care Services (Provider Selection Regime) Regulations 2023 and will not be competed via Public Contract Regulations 2015 or via the Procurement Act 2023.<br/><br/>The Contracting Authority will be using Atamis, the Contracting Authority’s e-Tendering system for this procurement exercise. For further information, the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system.<br/><br/>Only Tenders which pass the applicable compliance checks and all applicable Pass/Fail requirements in Questionnaire 1 – the Basic Selection Criteria Questionnaire in accordance with Document 1 – ITT Instructions, will proceed to Stage 2 evaluation.<br/><br/>Stage 1 (Compliance and Basic Selection Criteria Questionnaire)<br/>Compliance checks will be completed to ensure tenders are completed as per the ITT instructions. The Basic Selection Criteria Questionnaire will evaluate the Basic Selection Criteria. The questions will be evaluated on a Pass/Fail or for information only basis and can be found in Document 3.<br/><br/>Stage 2 (Quality, Social Value and Commercial Envelope)<br/>This will be the evaluation of the Quality and Commercial envelope which contains the Key Criteria questions and can be found in Document 4 (Quality and Social Value Envelope) and Document 5 (Commercial Envelope). Scores from Stage 2 evaluation will form 20% of the final score at Stage 3 evaluation.<br/><br/>The Key Criteria (as outlined in PSR Regulation 5) for Stage 2 will be evaluated as outlined below:<br/><br/>1. National MRI reporting service model and governance - 8%<br/><br/>National service model, governance, accountability, subcontracting/reporting networks and pathway interfaces.<br/><br/>2. Reader workforce, competence, capacity and onboarding - 16%<br/><br/>Reader credentials and experience, training, QA, workforce capacity, resilience and performance management.<br/><br/>3. Image receipt, Scanning Organisation interface and digital interoperability - 12%<br/><br/>Image transfer/access, interfaces, matching, case acceptance, image quality, reconciliation, downtime and IG.<br/><br/>4. Reporting protocol, double reading, arbitration and structured report - 16%<br/><br/>Human double reading, arbitration, lesion delineation, Structured Report, incidental findings, QA and reporting compliance.<br/><br/>5. Report return, urgent findings, Failsafe and onward pathway liaison - 10%<br/><br/>Report return/acknowledgement, urgent findings, failed handoffs, Failsafe, escalation and downstream liaison.<br/><br/>6. Mobilisation, performance monitoring, resilience and business continuity - 8%<br/><br/>Mobilisation, onboarding, testing, KPIs, audit, capacity, BCP, recovery and reconciliation.<br/><br/>7. Social Value – equitable access, workforce sustainability and low-carbon delivery – 10%<br/><br/>Key areas assessed: equitable access to specialist MRI reporting, sustainable specialist workforce, fair work, training/wellbeing, ethical subcontracting, remote/digital delivery and low-carbon operational practices.<br/><br/>PSR Key Criteria<br/><br/>In accordance with Regulation 5 of the Health Care Services (Provider Selection Regime) Regulations 2023, the award criteria collectively assess all five PSR Key Criteria as follows:<br/><br/>Quality and Innovation – assessed through Questions 1–6 of the Quality Envelope, including service quality, specialist reader capability, digital interoperability, reporting methodology, clinical Failsafe arrangements, mobilisation and resilience.<br/><br/>Value – assessed through the Commercial Envelope, weighted at 20%.<br/><br/>Integration, Collaboration and Service Sustainability – assessed principally through Questions 1, 2, 3, 5 and 6, including governance, specialist workforce sustainability, Scanning Organisation interfaces, digital interoperability, pathway handoffs, capacity and business continuity.<br/><br/>Improving Access, Reducing Health Inequalities and Facilitating Choice – assessed principally through Questions 1, 3, 5 and 7, including national access to specialist reporting, Scanning Organisation connectivity, Failsafe/pathway liaison and additional equitable-access commitments.<br/><br/>Social Value – assessed through Question 7, weighted at 10%.<br/><br/>Stage 2 - Commercial Envelope - 20%<br/><br/>This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 or Procurement Act 2023 do not apply to this award.£143.7k